Prognostic biomarkers in renal cell carcinoma

Expert Review of Molecular Diagnostics

Volumn 7, Issue 3, 2007, Pages 293-307

  Jiang, Zhong ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

B7 H1; Biomarker; CA9; IMP3; Metastasis; Prognosis; Renal cell carcinoma

Indexed keywords

ADIPOPHILIN; B7 ANTIGEN; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CATENIN; EPITHELIAL CELL ADHESION MOLECULE; GELATINASE A; GELATINASE B; HERMES ANTIGEN; MUCIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; RNA BINDING PROTEIN; SOMATOMEDIN; UVOMORULIN; VIMENTIN;

ANGIOGENESIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; METASTASIS; PLOIDY; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

ANIMALS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249095547     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.3.293     Document Type: Review

References (119)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335(12), 865-875 (1996).
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353(23), 2477-2490 (2005).
3. Chow WH, Devesa SS, Warren JL et al. Rising incidence of renal cell cancer in the United States. JAMA 281(17), 1628-1631 (1999).
4. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. Cancer J. Clin. 55(1), 10-30 (2005).
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163(2), 408-417 (2000).
6. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006).
7. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24(35), 5601-5608 (2006).
8. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
9. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
10. Tsui KH, Shvarts O, Smith RB et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J. Urol. 163(4), 1090-1095 (2000).
11. Sene AP, Hunt L, McMahon RF et al. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br. J. Urol. 70(2), 125-134 (1992).
12. Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol. Clin. North Am. 20(2), 263-275 (1993).
13. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol. Clin. North Am. 20(2), 247-262 (1993).
14. Rabinovitch RA, Zelefsky MJ, Gaynor JJ et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol. 12(1), 206-212 (1994).
15. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J. Urol. 154(1), 28-31 (1995).
16. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7(1), 85-90 (1994).
17. Shuin T, Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54(11), 2852-2855 (1994).
18. Iliopoulos O, Kibel A, Gray S et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1(8), 822-826 (1995).
19. Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94(20), 1569-1575 (2002).
20. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196(2), 186-193 (2002).
21. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999).
22. Iliopoulos O, Levy AP, Jiang C et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93(20), 10595-10599 (1996).
23. Na X, Wu G, Ryan CK et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 a expression in renal cell carcinomas. J. Urol. 170(2 Pt 1), 588-592 (2003).
24. Fukata S, Inoue K, Kamada M et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103(5), 931-942 (2005).
25. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int. J. Urol. 2(3), 156-160 (1995).
26. Jacobsen J, Rasmuson T, Grankvist K et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 163(1), 343-347 (2000).
27. Yildiz E, Gokce G, Kilicarslan H et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 93(7), 1087-1093 (2004).
28. Joo HJ, Oh DK, Kim YS et al. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 93(3), 291-296 (2004).
29. Lee JS, Kim HS, Jung JJ et al. Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J. Surg. Oncol. 77(1), 55-60 (2001).
30. Gelb AB, Kim HS, Jung JJ et al. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 80(9), 1768-1775 (1997).
31. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 46(1), 27-30 (1995).
32. Minardi D, Lucarini G, Mazzucchelli R et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J. Urol. 174(4 Pt 1), 1208-1212 (2005).
33. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 23(33), 5624-5631 (2004).
34. Liao SY, Aurelio ON, Jan K et al. Identification of the MN/CAIX protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57(14), 2827-2831 (1997).
35. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
36. Shvarts O, Seligson D, Lam J et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol. 173(3), 725-728 (2005).
37. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11(10), 3714-3721 (2005).
38. Yao M, Tabuchi H, Nagashima Y et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205(3), 377-387 (2005).
39. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351(6326), 453-456 (1991).
40. Cross SM, Sanchez CA, Morgan CA et al. A p53-dependent mouse spindle checkpoint. Science 267(5202), 1353-1356 (1995).
41. Uhlman DL, Nguyen PL, Manivel JC et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl Cancer Inst. 86(19), 1470-1475 (1994).
42. Moch H, Sauter G, Gasser TC et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol. Res. 25(Suppl 1), S25-S30 (1997).
43. Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 173(5), 1496-1501 (2005).
44. Girgin C, Tarhan H, Hekimgil M et al. p53 mutations and other prognostic factors of renal cell carcinoma. Urol. Int. 66(2), 78-83 (2001).
45. Shiina H, Igawa M, Urakami S et al. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur. Urol. 31(1), 73-80 (1997).
46. Bot FJ, Godschalk JC, Krishnadath KK et al. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinicopathological parameters. Int. J. Cancer 57(5), 634-637 (1994).
47. Hofmockel G, Wittmann A, Dammrich J et al. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res. 16(6B), 3807-3811 (1996).
48. Papadopoulos I, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur. Urol. 32(1), 110-117 (1997).
49. Kramer BA, Gao X, Davis M et al. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J. Am. Coll. Surg. 201 (4), 565-570 (2005).
50. Ljungberg B, Bozoky B, Kovacs G et al. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scan. J. Urol. Nephrol. 35(1), 15-20 (2001).
51. Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7), 1237-1245 (1992).
52. Wu X, Bayle JH, Olson D et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7(7A), 1126-1132 (1993).
53. Haitel A, Wiener HG, Baethge U et al. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 6(5), 1840-1844 (2000).
54. Hedberg Y, Davoodi E, Ljungberg B et al. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int. J. Cancer 102(6), 601-607 (2002).
55. Migita T, Oda Y, Naito S et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 94(4), 973-979 (2002).
56. Aaltomaa S, Lipponen P, Ala-Opas M et al. Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br. J. Cancer 80(12), 2001-2007 (1999).
57. Hedberg Y, Davoodi E, Roos G et al. Cyclin-D 1 expression in human renal-cell carcinoma. Int. J. Cancer 84(3), 268-272 (1999).
58. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308), 1943-1947 (1997).
59. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 99(1), 53-57 (2002).
60. Velickovic M, Delahunt B, McIver B et al. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod. Pathol. 15(5), 479-485 (2002).
61. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer 91(2), 219-224 (2001).
62. Shin Lee J, Seok Kim H, Bok Kim Y et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol. 84(3), 166-172 (2003).
63. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10(16), 5464-5471 (2004). • A large study of protein expression profiles of multiple prognostic biomarkers for renal cell carcinoma.
64. Rioux-Leclercq N, Turlin B, Bansard J et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 55(4), 501-505 (2000).
65. Tannapfel A, Hahn HA, Katalinic A et al. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 77(1), 164-171 (1996).
66. Haitel A, Wiener HG, Migschitz B et al. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas? Am. J. Clin. Pathol. 107(2), 229-235 (1997).
67. Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27(5), 612-624 (2003).
68. Cronin KJ, Williams NN, Kerin MJ et al. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J. Urol. 152(3), 834-836 (1994).
69. Hofmockel G, Tsatalpas P, Muller H et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 76(2), 296-306 (1995).
70. Abou-Rebyeh H, Borgmann V, Nagel R et al. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer 92(9), 2280-2285 (2001).
71. Di Silverio F, Casale P, Colella D et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 88(4), 835-843 (2000).
72. Jochum W, Schroder S, al-Taha R et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 77(3), 514-521 (1996).
73. Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br. J. Cancer 71(2), 376-379 (1995).
74. Shimazui T, Oosterwijk E, Akaza H et al. Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin. Cancer Res. 4(10), 2419-2424 (1998).
75. Shimazui T, Bringuier PP, van Berkel H et al. Decreased expression of α-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int. J. Cancer 74(5), 523-528 (1997).
76. Slaton JW, Inoue K, Perrotte P et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am. J. Pathol. 158(2), 735-743 (2001).
77. Gilcrease MZ, Guzman-Paz M, Niehans G et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86(11), 2320-2326 (1999).
78. Paradis V, Ferlicot S, Ghannam E et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J. Urol. 161(6), 1984-1987 (1999).
79. Li N, Tsuji M, Kanda K et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int. 85(4), 514-518 (2000).
80. Seligson DB, Pantuck AJ, Liu X et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res. 10(8), 2659-2669 (2004).
81. Nieminen M, Henttinen T, Merinen M et al. Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol. 8(2), 156-162 (2006).
82. Sabo E, Miselevich I, Bejar J et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br. J. Urol. 80(6), 864-868 (1997).
83. Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer 80(1-2), 301-308 (1999).
84. Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am. J. Clin. Pathol. 118(1), 47-51 (2002).
85. Kraus S, Abel PD, Nachtmann C et al. MUC 1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum. Pathol. 33(1), 60-67 (2002).
86. Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5(12), 1365-1369 (1999).
87. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. [erratum appears in Nat. Med. 8(9),1039 (2002)]. Nat. Med. 8(8), 793-800 (2002).
88. Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170(3), 1257-1266 (2003).
89. Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10(15), 5094-5100 (2004).
90. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
91. Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63(21), 7462-7467 (2003).
92. + T cells. Cancer Res. 64(3), 1140-1145 (2004).
93. Thompson RH, Webster WS, Cheville JC et al. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology 66(5 Suppl.), 10-14 (2005).
94. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101 (49), 17174-17179 (2004).
95. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104(10), 2084-2091 (2005).
96. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006). • Definitive paper that describes a new prognostic biomarker for renal cell carcinoma.
97. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6), 849-861 (2003).
98. Choi IH, Zhu G, Sica GL et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171(9), 4650-4654 (2003).
99. Salceda S, Tang T, Kmet M et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell. Res. 306(1), 128-141 (2005).
100. Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103(27), 10391-10396 (2006).
101. Mueller-Pillasch F, Pohl B, Wilda M et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 88(1), 95-99 (1999).
102. Nielsen J, Christiansen J, Lykke-Andersen J et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol. 19(2), 1262-1270 (1999).
103. Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14(22), 2729-2733 (1997).
104. Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br. J. Cancer 88(6), 887-894 (2003).
105. Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol. 29(2), 188-195 (2005).
106. Liao B, Hu Y, Herrick DJ et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 280(18), 18517-18524 (2005).
107. Yaniv K, Fainsod A, Kalcheim C et al. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development 130(23), 5649-5661 (2003).
108. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25(7), 1456-1468 (2006).
109. Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7(7), 556-564 (2006). • First report and a large study of a new prognostic biomarker that can predict tumor progression and metastasis for renal cell carcinoma.
110. Zhao H, Ljungber B, Grankvist K et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3(1), e13 (2006).
111. Moch H, Schraml P, Bubendorf L et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154(4), 981-986 (1999).
112. Hoffmann R, Franzke A, Buer J et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br. J. Cancer 79(11-12), 1742-1745 (1999).
113. Rasmuson T, Grankvist K, Jacobsen J et al. Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol. 43(8), 744-748 (2004).
114. Eggener SE, Yossepowitch O, Pettus JA et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J. Clin. Oncol. 24(19), 3101-3106 (2006).
115. Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
116. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2(8), 416-422 (2005). • Important guideline for the studies of prognostic biomarkers.
117. Takahashi M, Sugimura J, Yang X et al. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv. Cancer Res. 89, 157-181 (2003).
118. Frank I, Blute ML, Cheville JC et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor Stage, SIze, Grade and Necrosis: the SSIGN score. J. Urol. 168(6), 2395-2400 (2002).
119. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19(6), 1649-1657 (2001).